Menu
Search
|

Menu

Close
X

Ritter Pharmaceuticals Inc RTTR.OQ (NASDAQ Stock Exchange Capital Market)

0.30 USD
-- (--)
As of Feb 22
chart
Previous Close 0.30
Open --
Volume --
3m Avg Volume 123,300
Today’s High --
Today’s Low --
52 Week High 3.37
52 Week Low 0.27
Shares Outstanding (mil) 49.51
Market Capitalization (mil) 14.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.421
FY16
-2.000
FY15
-1.852
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
3.67
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-430.95
13.67
Return on Equity (TTM)
vs sector
-430.95
15.40

EXECUTIVE LEADERSHIP

Ira Ritter
Executive Chairman of the Board, Chief Strategic Officer, Since 2014
Salary: $308,332.00
Bonus: $97,571.00
Michael Step
Chief Executive Officer, Director, Since 2014
Salary: $376,269.00
Bonus: --
Jeffrey Benjamin
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Since 2017
Salary: --
Bonus: --
Andrew Ritter
President, Founder, Director, Since 2014
Salary: $324,010.00
Bonus: $117,180.00
Noah Doyle
Independent Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1880 Century Park E Ste 1000
LOS ANGELES   CA   90067-1623

Phone: +1310.2031000

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

SPONSORED STORIES